Zanubrutinib Oral Product

Phase 2

BeiGene, Ltd. (BGNE)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

BGNEPhase 2

Zanubrutinib Oral Product Phase 2 Est. Readout

Zanubrutinib Oral Product• Monoclonal Gammopathy of Uncertain Significance35

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Monoclonal Gammopathy of Uncertain Significance

View Full Landscape

Drug Information

Target Indication

Monoclonal Gammopathy of Uncertain Significance

Clinical Trial

NCT05939037

Last updated: 8/20/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BGNE

BeiGene, Ltd.

Biotechnology•North America•NASDAQ

Related Pipeline

ZanubrutinibPhase 3

Refractory Mantle Cell Lymphoma

TislelizumabPhase 3

Urothelial Carcinoma

Gemcitabine HydrochloridePhase 3

Urothelial Carcinoma

Cisplatin injectionPhase 3

Non Small Cell Lung Cancer

BGB-16673Phase 3

Chronic Lymphocytic Leukemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts